Piper Sandler Maintains Overweight on Solid Biosciences, Raises Price Target to $18
Benzinga Newsdesk 5 months ago
NewsPrice TargetAnalyst Ratings
Piper Sandler analyst Biren Amin maintains Solid Biosciences (NASDAQ:SLDB) with a Overweight and raises the price target from $17 to $18.
Piper Sandler analyst Biren Amin maintains Solid Biosciences (NASDAQ:SLDB) with a Overweight and raises the price target from $17 to $18.